X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (269) 269
Book Chapter (7) 7
Book Review (3) 3
Web Resource (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (139) 139
life sciences & biomedicine (137) 137
oncology (126) 126
humans (125) 125
female (75) 75
lung neoplasms - drug therapy (71) 71
male (70) 70
carcinoma, non-small-cell lung - drug therapy (66) 66
aged (62) 62
middle aged (59) 59
lung cancer (48) 48
adult (45) 45
lung neoplasms - pathology (39) 39
immunotherapy (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
antineoplastic agents - therapeutic use (33) 33
carcinoma, non-small-cell lung - pathology (33) 33
cancer (31) 31
aged, 80 and over (30) 30
treatment outcome (30) 30
neoplasm staging (29) 29
chemotherapy (28) 28
antibodies, monoclonal - therapeutic use (26) 26
care and treatment (23) 23
lung neoplasms - mortality (23) 23
neoplasms - drug therapy (22) 22
respiratory system (22) 22
carcinoma, non-small-cell lung - mortality (21) 21
lung neoplasms - genetics (20) 20
lung neoplasms - immunology (20) 20
patients (20) 20
lung cancer, non-small cell (19) 19
mutation (19) 19
carcinoma, non-small-cell lung - genetics (18) 18
prognosis (18) 18
survival rate (18) 18
non-small cell lung cancer (17) 17
antibodies, monoclonal - adverse effects (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
apoptosis (16) 16
carcinoma, non-small-cell lung - immunology (16) 16
antineoplastic agents - adverse effects (15) 15
nivolumab (15) 15
non-small cell lung carcinoma (15) 15
programmed cell death 1 receptor - antagonists & inhibitors (15) 15
research (15) 15
abridged index medicus (14) 14
drug therapy (14) 14
general & internal medicine (14) 14
medicine & public health (14) 14
tumors (14) 14
antibodies, monoclonal - administration & dosage (13) 13
bevacizumab (13) 13
medicine, general & internal (13) 13
cancer therapies (12) 12
dose-response relationship, drug (12) 12
follow-up studies (12) 12
lung neoplasms - therapy (12) 12
pulmonary and respiratory medicine (12) 12
survival analysis (12) 12
animals (11) 11
b7-h1 antigen - antagonists & inhibitors (11) 11
immunotherapy - methods (11) 11
melanoma (11) 11
original reports (11) 11
pd-l1 protein (11) 11
programmed cell death 1 receptor - immunology (11) 11
analysis (10) 10
carboplatin - administration & dosage (10) 10
carcinoma, non-small-cell lung - therapy (10) 10
disease-free survival (10) 10
immunology (10) 10
metastasis (10) 10
quality of life (10) 10
time factors (10) 10
antineoplastic agents - pharmacology (9) 9
clinical trials (9) 9
clinical trials as topic (9) 9
cohort studies (9) 9
dosage and administration (9) 9
retrospective studies (9) 9
antineoplastic agents, immunological - therapeutic use (8) 8
disease progression (8) 8
drug administration schedule (8) 8
erlotinib hydrochloride (8) 8
ipilimumab (8) 8
ligands (8) 8
lung neoplasms (8) 8
molecular targeted therapy (8) 8
paclitaxel - administration & dosage (8) 8
protein kinase inhibitors - therapeutic use (8) 8
respiratory tract diseases (8) 8
antibodies, monoclonal - pharmacology (7) 7
antibodies, monoclonal, humanized (7) 7
antineoplastic agents - administration & dosage (7) 7
antineoplastic agents, immunological - adverse effects (7) 7
b7-h1 antigen - immunology (7) 7
immune checkpoint (7) 7
kaplan-meier estimate (7) 7
melanoma - drug therapy (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 03/2013, Volume 31, Issue 8, pp. 1021 - 1028
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2015, Volume 373, Issue 17, pp. 1627 - 1639
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
Journal Article
Seminars in oncology, ISSN 0093-7754, 02/2014, Volume 41, Issue 1, pp. 126 - 132
Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Cancer Vaccines - therapeutic use | Lung Neoplasms - immunology | Animals | Humans | Immunotherapy | Antibodies, Monoclonal - therapeutic use
Journal Article
3/2015, Volume 7, Issue 2, 12
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player... 
non-small cell lung cancer | programmed death-1 ligand | programmed death-1 | nivolumab | immune checkpoint modulator | Life Sciences & Biomedicine | Oncology | Science & Technology | Reviews
Book Review
2007, 1, Translational medicine series, ISBN 9780849390210, Volume 3, viii, 265
Lung cancer is the leading cause of cancer-related deaths in the United States. Filling a gap in the literature, this resource translates recent laboratory... 
Chemotherapy | Treatment | drug therapy | Lungs | Antineoplastic Agents | Technological innovations | Lung Neoplasms | Molecular aspects | therapeutic use | Cancer | Oncology | Pulmonary Medicine | Lungs - Cancer - Molecular aspects
Book
The New England journal of medicine, ISSN 1533-4406, 11/2016, Volume 375, Issue 19, pp. 1823 - 1833
Journal Article